A three-month business review by Gene Logic, has confirmed the potential of its drug repositioning and restructured genomics units. According to a company statement, its genomics assets are a key part of the technology platform used in its drug repositioning business. The company is exploring the possibility of using the assets and technologies in areas such as clinical biomarker development and molecular diagnostics. According to Gene Logic, the review revealed that its prior strategy for...